MR/ultrasound fusion boosts prostate biopsy performance

By Kate Madden Yee, staff writer

November 4, 2015 --

Tuesday, December 1 | 3:10 p.m.-3:20 p.m. | SSJ10-02 | Room E353C
Using MR/ultrasound fusion improves the performance of prostate biopsies when compared with random ultrasound-guided biopsies, according to this study to be presented on Tuesday afternoon.

Researchers led by Dr. Guilherme Mariotti of Hospital Sírio-Libanês in São Paulo conducted a retrospective study of 261 patients who underwent targeted prostate biopsies using MR/ultrasound fusion between August 2013 and January 2015. All of the patients had preprocedure MR exams, which were categorized for suspicion of cancer based on a six-point Likert scale.

MR/ultrasound fusion identified 154 cases (59%) as positive for cancer, with 123 cases of significant cancer (79%), 30 cases of nonsignificant cancer (19%), and one stromal tumor of uncertain malignancy.

In comparison, the positivity rate was approximately 52% for ultrasound-guided random biopsies in a sample of 331 patients during the same period.

The study findings suggest that targeted prostate biopsies using MR/ultrasound fusion increase the accuracy of the procedure, which leads to better clinical outcomes, the researchers concluded.

Last Updated hh 10/30/2015 3:23:29 PM